CIK: 0002050709
Total reported value
$272.9M
Reporting period: 2026-03-31 · Number of holdings: 37
Squadron Capital Management LLC disclosed 37 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $272.9M and a quarterly turnover rate of 87.8%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "S"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add RLMD
+26.5% $26.6M
Trim MAZE
-47.4% -$12.6M
Add 4XC1
+85.7% $14.9M
Trim ABVX
-10.3% -$5.1M
Trim PALI
-33.3% -$5.3M
Trim SPRB
-82.6% -$5.3M
Showing top 33 holdings (of 37 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RLMD | Relmada Therapeutics INC | Stock-Other | 21.61% | +7.90% | +26.49% | |
| 2 | COGT | Cogent Biosciences INC | Stock-Other | 11.11% | -0.63% | +0.96% | |
| 3 | 4XC1 | Kalvista Pharmaceuticals INC | Stock-Other | 9.59% | +4.80% | +85.73% | |
| 4 | KOD | Kodiak Sciences INC | Stock-Other | 5.31% | +1.85% | +30.27% | |
| 5 | ABVX | Abivax Sa-adr | Stock-Other | 5.30% | -2.99% | -10.34% | |
| 6 | EWTX | Edgewise Therapeutics INC | Stock-Other | 4.04% | +0.36% | — | |
| 7 | ZNTL | Zentalis Pharmaceuticals INC | Stock-Other | 3.46% | +3.46% | NEW | |
| 8 | NKTR | Nektar Therapeutics | Stock-Other | 3.30% | +3.30% | NEW | |
| 9 | ANL | Adlai Nortye Ltd-adr | Stock-Other | 3.21% | +3.21% | NEW | |
| 10 | RLAY | Relay Therapeutics INC | Stock-Other | 3.00% | +3.00% | NEW | |
| 11 | MAZE | Maze Therapeutics INC | Stock-Other | 2.82% | -5.78% | -47.45% | |
| 12 | IDYA | Ideaya Biosciences INC | Stock-Other | 2.74% | +2.74% | NEW | |
| 13 | SCYXEUR | Scynexis INC | Stock-Other | 2.56% | +2.56% | NEW | |
| 14 | CCCC | C4 Therapeutics INC | Stock-Other | 2.17% | +2.17% | NEW | |
| 15 | IKT | Inhibikase Therapeutics INC | Stock-Other | 2.15% | -1.52% | -17.16% | |
| 16 | PALI | Palisade Bio INC | Stock-Other | 1.92% | -2.56% | -33.33% | |
| 17 | EPRX | Eupraxia Pharmaceuticals INC | Stock-Other | 1.80% | +0.20% | +36.00% | |
| 18 | GHRS | GH Research PLC | Stock-Other | 1.67% | -0.03% | +3.17% | |
| 19 | KPTI | Karyopharm Therapeutics INC | Stock-Other | 1.53% | +1.53% | NEW | |
| 20 | PMN | Promis Neurosciences INC | Stock-Other | 1.51% | +1.51% | NEW | |
| 21 | LPCN | Lipocine INC | Stock-Other | 1.32% | -0.48% | -15.09% | |
| 22 | IVA | Inventiva SA - Adr | Stock-Other | 1.09% | +0.50% | +78.33% | |
| 23 | ALXO | Alx Oncology Holdings INC | Stock-Other | 1.07% | +1.07% | NEW | |
| 24 | CNTX | Context Therapeutics INC | Stock-Other | 1.06% | +1.06% | NEW | |
| 25 | NXTC | Nextcure INC | Stock-Other | 1.04% | -0.38% | +11.83% | |
| 26 | AVBP | Arrivent Biopharma INC | Stock-Other | 0.93% | -1.95% | -67.46% | |
| 27 | ✓ | Stock-Other | 0.90% | +0.90% | NEW | ||
| 28 | KTTA | Pasithea Therapeutics CORP | Stock-Other | 0.57% | -0.58% | — | |
| 29 | TRAW | Traws Pharma INC | Stock-Other | 0.34% | — | -28.29% | |
| 30 | TXMD | Therapeuticsmd INC | Stock-Other | 0.31% | +0.31% | NEW | |
| 31 | SPRB | Spruce Biosciences INC | Stock-Other | 0.29% | -2.29% | -82.57% | |
| 32 | HOWL | Werewolf Therapeutics INC | Stock-Other | 0.17% | +0.17% | NEW | |
| 33 | NEUP | Neuphoria Therapeutics INC | Stock-Other | 0.11% | +0.11% | NEW |
Performance for Q3 2026
-2.2%
Performance Last 4 Quarters
+2.6%
Based on 5 months of available history
Based on 81% of reported portfolio value with available pricing
Not enough sector-mapped data yet
Squadron Capital Management LLC's most significant position changes for 2026-03-31: New buy: Zentalis Pharmaceuticals INC (ZNTL); New buy: Nektar Therapeutics (NKTR); New buy: Adlai Nortye Ltd-adr (ANL); New buy: Relay Therapeutics INC (RLAY); Sold out: Terns Pharmaceuticals INC (430).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RLMD | Relmada Therapeutics INC | +7.9% | +26.49% | Add |
| 2 | 4XC1 | Kalvista Pharmaceuticals INC | +4.8% | +85.73% | Add |
| 3 | KOD | Kodiak Sciences INC | +1.9% | +30.27% | Add |
| 4 | IVA | Inventiva SA - Adr | +0.5% | +78.33% | Add |
| 5 | EWTX | Edgewise Therapeutics INC | +0.4% | — | Unchanged |
| 6 | EPRX | Eupraxia Pharmaceuticals INC | +0.2% | +36.00% | Add |
| 7 | TRAW | Traws Pharma INC | — | -28.29% | Trim |
| 8 | GHRS | GH Research PLC | 0% | +3.17% | Add |
| 9 | NXTC | Nextcure INC | -0.4% | +11.83% | Add |
| 10 | LPCN | Lipocine INC | -0.5% | -15.09% | Trim |
| 11 | KTTA | Pasithea Therapeutics CORP | -0.6% | — | Unchanged |
| 12 | COGT | Cogent Biosciences INC | -0.6% | +0.96% | Add |
| 13 | IKT | Inhibikase Therapeutics INC | -1.5% | -17.16% | Trim |
| 14 | AVBP | Arrivent Biopharma INC | -2% | -67.46% | Trim |
| 15 | SPRB | Spruce Biosciences INC | -2.3% | -82.57% | Trim |
| 16 | PALI | Palisade Bio INC | -2.6% | -33.33% | Trim |
| 17 | ABVX | Abivax Sa-adr | -3% | -10.34% | Trim |
| 18 | MAZE | Maze Therapeutics INC | -5.8% | -47.45% | Trim |
| 19 | ZNTL | Zentalis Pharmaceuticals INC | — | NEW | New buy |
| 20 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 21 | ANL | Adlai Nortye Ltd-adr | — | NEW | New buy |
| 22 | RLAY | Relay Therapeutics INC | — | NEW | New buy |
| 23 | 430 | Terns Pharmaceuticals INC | — | EXIT | Sold out |
| 24 | IDYA | Ideaya Biosciences INC | — | NEW | New buy |
| 25 | SCYXEUR | Scynexis INC | — | NEW | New buy |
| 26 | TARS | Tarsus Pharmaceuticals INC | — | EXIT | Sold out |
| 27 | UPB | Upstream Bio INC | — | EXIT | Sold out |
| 28 | CCCC | C4 Therapeutics INC | — | NEW | New buy |
| 29 | XENE | Xenon Pharmaceuticals INC | — | EXIT | Sold out |
| 30 | DBVT | Dbv Technologies Sa-spon Adr | — | EXIT | Sold out |
| 31 | HELP | Cybin INC | — | EXIT | Sold out |
| 32 | KPTI | Karyopharm Therapeutics INC | — | NEW | New buy |
| 33 | BLTE | Belite Bio INC - Adr | — | EXIT | Sold out |
| 34 | PMN | Promis Neurosciences INC | — | NEW | New buy |
| 35 | VTYXUSD | Ventyx Biosciences INC | — | EXIT | Sold out |
| 36 | VERA | Vera Therapeutics INC | — | EXIT | Sold out |
| 37 | WVE | Wave Life Sciences Ltd. | — | EXIT | Sold out |
| 38 | ALXO | Alx Oncology Holdings INC | — | NEW | New buy |
| 39 | CNTX | Context Therapeutics INC | — | NEW | New buy |
| 40 | CMPS | Compass Pathways PLC | — | EXIT | Sold out |
| 41 | ✓ | — | NEW | New buy | |
| 42 | AVTX | Avalo Therapeutics INC | — | EXIT | Sold out |
| 43 | ZBIO | Zenas Biopharma INC | — | EXIT | Sold out |
| 44 | TXMD | Therapeuticsmd INC | — | NEW | New buy |
| 45 | NTLA | Intellia Therapeutics INC | — | EXIT | Sold out |
| 46 | HOWL | Werewolf Therapeutics INC | — | NEW | New buy |
| 47 | CLYM | Climb Bio INC | — | EXIT | Sold out |
| 48 | NEUP | Neuphoria Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001302815
Total reported value
$272.8M
93 stks
2025-12-31
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001894164
Total reported value
$273.0M
190 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001802868
Total reported value
$272.7M
54 stks
2026-06-30
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001335325
Total reported value
$362.2M
156 stks
2026-03-31
2 of the top 5 holdings overlap, including Abivax Sa-adr
CIK 0001816307
Total reported value
$979.8M
73 stks
2026-03-31
2 of the top 5 holdings overlap, including Kalvista Pharmaceuticals INC
CIK 0001839435
Total reported value
$903.6M
29 stks
2026-03-31
2 of the top 5 holdings overlap, including Cogent Biosciences INC